|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
|
24965471 |
2014 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The occurrence of five sense mutations [S391A, G397A, L402F and M405T in the hypervariable region 1 (HVR1) of envelope glycoprotein 2 and I2750M in NS5B] suggested that HCV undergoes genetic evolution during culture.
|
28758632 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used a bioinformatics and functional approach to investigate whether E1/E2 envelope glycoprotein structure and function were associated with treatment failure in 92 patients infected with HCV genotype 1.
|
23335805 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we rescued a recombinant PR8 influenza viral vector, called rgFLU-HCV<sub>CE1E2</sub>, carrying the core and envelope glycoprotein (C/E1/E2) epitopes of HCV inserted into the influenza nonstructural protein 1 gene.
|
28778831 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicate that the antibody response to HCV E2 is affected by the genotype of the virus and that induction of a strong humoral immune response to HCV E2 may contribute to a decreased viral load.
|
11505439 |
2001 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibodies against envelope glycoprotein 1 and 2 (anti-E1/E2) have been suggested to influence HCV replication levels.
|
15042645 |
2004 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Confocal analysis showed that accumulation of occludin in the ER partially co-localized with HCV envelope glycoprotein E2.
|
18802961 |
2008 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HCV polyprotein contains a hypervariable region (HVR1) located at the N terminus of the second envelope glycoprotein E2.
|
11356980 |
2001 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF inhibits HCV infection despite increased HCV envelope glycoprotein-mediated infection of liver cells.
|
28456632 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypervariable region I (HVRI) of the putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV) undergoes sequential alterations at intervals of several months during the chronic phase of hepatitis.
|
7515022 |
1994 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hypervariable region 1 (HVR1) that includes the first 27 amino acid residues of the E2 envelope glycoprotein is the most variable region within the HCV polyprotein.
|
22927442 |
2012 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report the generation and application of a combinatorial library of HCV strain JFH1 envelope glycoprotein to profile the antibody response in four HCV chronically infected individuals.
|
25274855 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers.
|
29443378 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.
|
29951061 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.
|
18343477 |
2008 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structural characterisation of the hepatitis C envelope glycoprotein E1 ectodomain derived from a mammalian and a yeast expression system.
|
18077062 |
2008 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that the E2/NS1 antibody tested exhibits no neutralizing activity in chronic HCV infection but may serve as a serological indicator of active virus replication.
|
8621173 |
1996 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular basis of benzimidazole inhibitors to hepatitis C virus envelope glycoprotein.
|
29745064 |
2018 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus.
|
31116791 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recombinant baculoviruses that produce a putative non-structural protein 1 (NS1) of hepatitis C virus (HCV), predicted to be the second envelope glycoprotein, were constructed.
|
7686870 |
1993 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the interaction of apoE with viral envelope glycoprotein E2 and HCV virions by immunoprecipitation.
|
26404951 |
2016 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Envelope glycoprotein 2 (E2) of hepatitis C virus contains 18 conserved cysteine (Cys) residues in its ectodomain.
|
24314653 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2.
|
19997645 |
2009 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used long-read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV infection to investigate the underlying viral population and evolutionary dynamics.
|
30602023 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
NEURL3 inhibits HCV assembly by directly binding viral E1 envelope glycoprotein to disrupt its interaction with E2, an action that requires its Neuralized homology repeat (NHR) domain but not the RING domain.
|
30111563 |
2018 |